Monoclonal antibody | |
---|---|
Type | Single-chain variable fragment |
Source | Humanized (from mouse) |
Target | Complement component 5 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
|
NY (what is this?) (verify) |
Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting[1] and angioplasty,[2][3] among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.[4]
Alexion, the developer of pexelizumab, stopped development when the phase 3 trial indicated the heart-attack drug is no better than placebo.[5]
Intracellular (initiation) |
| ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intracellular (reception) |
| ||||||||||||||
Extracellular |
| ||||||||||||||
Unsorted |
|